Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:APT NYSE:ELMD NASDAQ:OBIO NASDAQ:RXST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTAlpha Pro Tech$6.22-6.3%$4.83$4.25▼$7.50$63.86M0.861,039 shs85,113 shsELMDElectromed$26.69+2.9%$24.63$17.73▼$30.73$220.20M0.3955,489 shs6,489 shsOBIOOrchestra BioMed$3.83-2.0%$4.33$2.20▼$5.42$232.52M0.52202,084 shs22,010 shsRXSTRxSight$5.48-3.8%$7.01$5.30▼$16.74$227.87M1.24876,227 shs60,341 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTAlpha Pro Tech+3.11%+44.35%+47.23%+26.00%+41.88%ELMDElectromed-3.71%+1.29%+7.50%-7.59%+16.80%OBIOOrchestra BioMed-3.22%-1.51%-5.33%-6.24%+47.55%RXSTRxSight-2.56%-22.97%-16.54%-30.57%-56.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTAlpha Pro Tech$6.22-6.3%$4.83$4.25▼$7.50$63.86M0.861,039 shs85,113 shsELMDElectromed$26.69+2.9%$24.63$17.73▼$30.73$220.20M0.3955,489 shs6,489 shsOBIOOrchestra BioMed$3.83-2.0%$4.33$2.20▼$5.42$232.52M0.52202,084 shs22,010 shsRXSTRxSight$5.48-3.8%$7.01$5.30▼$16.74$227.87M1.24876,227 shs60,341 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTAlpha Pro Tech+3.11%+44.35%+47.23%+26.00%+41.88%ELMDElectromed-3.71%+1.29%+7.50%-7.59%+16.80%OBIOOrchestra BioMed-3.22%-1.51%-5.33%-6.24%+47.55%RXSTRxSight-2.56%-22.97%-16.54%-30.57%-56.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTAlpha Pro Tech 0.00N/AN/AN/AELMDElectromed 3.00Buy$36.6737.41% UpsideOBIOOrchestra BioMed 2.50Moderate Buy$14.25272.06% UpsideRXSTRxSight 1.93Reduce$9.4472.31% UpsideCurrent Analyst Ratings BreakdownLatest APT, OBIO, RXST, and ELMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026RXSTRxSight Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026RXSTRxSight Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$11.00 ➝ $9.005/7/2026RXSTRxSight Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.004/21/2026OBIOOrchestra BioMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/2/2026OBIOOrchestra BioMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026OBIOOrchestra BioMed Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.003/9/2026RXSTRxSight Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$10.00 ➝ $9.002/26/2026RXSTRxSight Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.002/26/2026RXSTRxSight UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$8.00 ➝ $9.002/26/2026RXSTRxSight Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$11.00 ➝ $10.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTAlpha Pro Tech$59.91M1.06$0.49 per share12.80$5.29 per share1.18ELMDElectromed$68.86M3.21$0.65 per share41.36$5.10 per share5.23OBIOOrchestra BioMed$33.48M6.85N/AN/A$0.95 per share4.03RXSTRxSight$134.48M1.69N/AN/A$6.70 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTAlpha Pro Tech$4.19M$0.3516.89N/AN/A6.99%6.70%5.76%N/AELMDElectromed$5.15M$1.0335.48N/AN/A11.34%15.71%13.37%N/AOBIOOrchestra BioMed-$52.70M-$1.13N/AN/AN/A-157.40%-184.17%-65.56%N/ARXSTRxSight-$38.94M-$1.13N/AN/AN/A-36.58%-17.01%-15.12%N/ALatest APT, OBIO, RXST, and ELMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2026Q4 2025OBIOOrchestra BioMed-$0.38$0.26+$0.64$0.26$0.93 million$30.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPTAlpha Pro TechN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTAlpha Pro TechN/A19.0011.21ELMDElectromedN/A5.104.74OBIOOrchestra BioMed0.276.456.43RXSTRxSightN/A10.208.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTAlpha Pro Tech22.69%ELMDElectromed40.82%OBIOOrchestra BioMed53.20%RXSTRxSight78.78%Insider OwnershipCompanyInsider OwnershipAPTAlpha Pro Tech15.00%ELMDElectromed10.50%OBIOOrchestra BioMed8.10%RXSTRxSight10.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTAlpha Pro Tech12010.22 million9.46 millionOptionableELMDElectromed1608.28 million7.36 millionOptionableOBIOOrchestra BioMed459.88 million55.39 millionNot OptionableRXSTRxSight22041.40 million37.24 millionOptionableAPT, OBIO, RXST, and ELMD HeadlinesRecent News About These CompaniesWells Fargo & Company Cuts RxSight (NASDAQ:RXST) Price Target to $9.00May 10 at 4:19 AM | americanbankingnews.comRxSight, Inc. (RXST) Q1 2026 Earnings Call TranscriptMay 9 at 5:00 PM | seekingalpha.comRxSight (NASDAQ:RXST) Given New $9.00 Price Target at Wells Fargo & CompanyMay 7, 2026 | marketbeat.comNeedham & Company LLC Cuts RxSight (NASDAQ:RXST) Price Target to $11.00May 7, 2026 | marketbeat.comRxSight Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comRxSight (NASDAQ:RXST) Issues Earnings Results, Misses Estimates By $0.07 EPSMay 6, 2026 | marketbeat.comRxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2026 | zacks.comRxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales OutlookMay 6, 2026 | globenewswire.comRxSight, Inc. (NASDAQ:RXST) Receives Average Rating of "Reduce" from BrokeragesMay 6, 2026 | americanbankingnews.comRxSight, Inc. (NASDAQ:RXST) Receives Consensus Recommendation of "Reduce" from BrokeragesMay 6, 2026 | marketbeat.comHow The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target ResetsMay 4, 2026 | finance.yahoo.comRxSight, Inc. to Present at the Bank of America Healthcare ConferenceApril 29, 2026 | globenewswire.comRxSight (RXST) to Release Earnings on WednesdayApril 29, 2026 | marketbeat.comRxSight, Inc. to Report First Quarter 2026 Financial Results on May 6April 22, 2026 | globenewswire.comHow The RxSight (RXST) Story Is Shifting With New Guidance And Street Price TargetsApril 19, 2026 | finance.yahoo.comRxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026April 8, 2026 | globenewswire.comHow The Story Is Shifting For RxSight (RXST) On Guidance Leadership And ValuationApril 5, 2026 | finance.yahoo.comRxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 2, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX)March 12, 2026 | theglobeandmail.comHow The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO ChangeMarch 7, 2026 | finance.yahoo.comRXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 GuidanceFebruary 26, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026The $100 Barrel Is Back: Trading The Hormuz Havoc By Jeffrey Neal Johnson | April 15, 2026Uber's Annual Product Showcase Reveals It Is Coming for Airbnb and BookingBy Jessica Mitacek | May 7, 2026APT, OBIO, RXST, and ELMD Company DescriptionsAlpha Pro Tech NYSE:APT$6.22 -0.42 (-6.31%) As of 11:01 AM Eastern This is a fair market value price provided by Massive. Learn more.Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, synthetic roof underlayment, and self-adhered roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.Electromed NYSE:ELMD$26.68 +0.76 (+2.91%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Orchestra BioMed NASDAQ:OBIO$3.83 -0.08 (-2.05%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.RxSight NASDAQ:RXST$5.48 -0.22 (-3.84%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
